Bacterial infection refers to the invasion of a host's tissue by a pathogenic bacteria.
Bacterial infections are infections caused by bacteria. An infectious bacterium reproduces quickly and gives off toxic chemicals which damages tissues. Common bacterial infections include pneumonia, ear infections, diarrhea, urinary tract infections, and skin disorders
|Cat. No.||Product Name||CAS No.||Information|
A fourth-generation synthetic fluoroquinolone, broad-spectrum antibacterial agent that is active against both Gram-positive and Gram-negative bacteria; inhibits DNA gyrase and topoisomerase IV.
Relebactam (MK-7655) is a novel β-lactamase inhibitor that inhibited both class A and C β-lactamases in vitro; effectively restored imipenem's activity against imipenem-resistant Pseudomonas and Klebsiella strains at clinically achievable concentrations; reduces imipenem MICs for Enterobacteriaceae with KPC carbapenemases from 16-64 mg/L to 0.12-1 mg/L at a concentration of 4 mg/L.
A potent inhibitor of bacterial enoyl-ACP reductase FabI; demonstrates MICs of 0.015 and 0.008 ug/ml for S. aureus ATCC 29213 and S. aureus ATCC 33592 (MRSA), respectively; demonstrates a Staphylococcus-specific spectrum of activity.
Macozinone (PBTZ-169, PBTZ169) is a potent, second-generation antituberculosis agent that inhibits DprE1 and displays nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro; PBTZ169 is less cytotoxic than BTZ043 and shows significantly better efficacy at lower concentrations in the murine model of chronic TB, inhibits DprE1 more efficiently than BTZ043.
PD 404182 (PD404182, PD-404182) is a heterocyclic iminobenzothiazine derivative with antimicrobial and anti-inflammatory properties, a potent inhibitor of human DDAH1 activity (IC50=9 uM) and elevates cellular ADMA levels; significantly increases intracellular levels of ADMA and reduces LPS-induced NO production in cultured primary human vascular endothelial cells (ECs), abrogates the formation of tube-like structures by ECs in in vitro angiogenesis assay; also shows anti-HIV and anti-HSV activites.
A novel fluoroketolide with lower MICs than those of telithromycin and macrolides; binds to the large 50S subunit of the ribosome and inhibits protein biosynthesis; exhibits MICs of 7.5, 40, and 125 ng/ml for Streptococcus pneumoniae,Staphylococcus aureus, and Haemophilus influenzae, respectively.
Epetraborole (GSK2251052, AN3365) is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS), shows MIC50/MIC90 of 2/4 ug/ml against 916 clinical anaerobic isolates; MIC90s against 302 Bacteroides fragilis and Bacteroides thetaiotaomicron strains are 4 and 8 μg/ml, respectively; a single amino acid polymorphism (P329) within the editing domain of LeuRS reduces susceptibility to GSK2251052.
A novel oxazolidinone antibiotic that shows good antibacterial activity (MSSA MIC50=1 ug/mL); potently inhibits MSSA and MRSA clinical isolates with MIC of 0.5-2 and 0.5-4 ug/mL, respectively; shows more-potent protective effects (MSSA ED50=4.53 mg/kg) than Linezolid against systemic infections caused by Gram-positive and Gram-negative bacteria in mice model.
An oxazolidinone antibiotic that possesses potent antituberculosis activity in vitro and in vivo; significantly shorten the duration of therapy for drug-susceptible as well as multidrug-resistant tuberculosis.
Fidaxomicin(OPT-80; PAR-101) is a new class of narrow spectrum macrocyclic antibiotic drug, selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria.
No.1378 West Wenyi Road, Yuhang District, HangZhou, Zhejiang, China